OTCMKTS:INBP Integrated BioPharma (INBP) Stock Price, News & Analysis $0.29 -0.01 (-3.33%) As of 04/17/2025 02:55 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsSEC FilingsShort InterestBuy This Stock About Integrated BioPharma Stock (OTCMKTS:INBP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Integrated BioPharma alerts:Sign Up Key Stats Today's Range$0.28▼$0.2950-Day Range$0.26▼$0.3452-Week Range$0.16▼$0.42Volume3,923 shsAverage Volume18,597 shsMarket Capitalization$8.79 millionP/E Ratio9.67Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewIntegrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.Read More… Integrated BioPharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreINBP MarketRank™: Integrated BioPharma scored higher than 50% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Integrated BioPharma. Earnings and Valuation1.9 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Integrated BioPharma is 9.67, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.40.Price to Earnings Ratio vs. SectorThe P/E ratio of Integrated BioPharma is 9.67, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.94.Price to Book Value per Share RatioIntegrated BioPharma has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Integrated BioPharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.02% of the float of Integrated BioPharma has been sold short.Short Interest Ratio / Days to CoverIntegrated BioPharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Integrated BioPharma has recently decreased by 66.67%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIntegrated BioPharma does not currently pay a dividend.Dividend GrowthIntegrated BioPharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.02% of the float of Integrated BioPharma has been sold short.Short Interest Ratio / Days to CoverIntegrated BioPharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Integrated BioPharma has recently decreased by 66.67%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News SentimentN/A News SentimentIntegrated BioPharma has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Integrated BioPharma this week, compared to 0 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Integrated BioPharma insiders have not sold or bought any company stock.Percentage Held by Insiders67.20% of the stock of Integrated BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 25.25% of the stock of Integrated BioPharma is held by institutions.Read more about Integrated BioPharma's insider trading history. Receive INBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Integrated BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address INBP Stock News HeadlinesIntegrated Biopharma Inc (INBP)September 1, 2024 | investing.comIntegrated BioPharma, Inc. (INBP)July 19, 2024 | finance.yahoo.comBREAKING: Trump Bans NVIDIA Chips to ChinaOn April 16th, 2025, President Trump banned Nvidia from selling its most advanced semiconductors to China. That brings the U.S. and China closer to war than at any time since the Korean War ended in 1953.April 20, 2025 | Behind the Markets (Ad)Integrated BioPharma Reports Results for its Quarter Ended December 31, 2023February 12, 2024 | finance.yahoo.comKBI Biopharma and Argonaut form drug manufacturing allianceJanuary 17, 2024 | msn.comKBI Biopharma, Inc. and Argonaut Manufacturing Services, Inc. Forge Strategic Alliance to Support Global Biopharmaceutical Companies with Integrated Drug Substance and Drug ...January 16, 2024 | businesswire.comJohnson & Johnson buys San Diego's Ambrx Biopharma for $2BJanuary 9, 2024 | msn.comWhat Is a Vertically Integrated Business Model?January 4, 2024 | smallbusiness.chron.comSee More Headlines INBP Stock Analysis - Frequently Asked Questions How have INBP shares performed this year? Integrated BioPharma's stock was trading at $0.3297 at the start of the year. Since then, INBP stock has decreased by 12.0% and is now trading at $0.29. View the best growth stocks for 2025 here. How do I buy shares of Integrated BioPharma? Shares of INBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Integrated BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Integrated BioPharma investors own include GSK (GSK), Invitae (NVTA), Exxon Mobil (XOM), Autodesk (ADSK), Adaptive Biotechnologies (ADPT), Analog Devices (ADI) and Adaptimmune Therapeutics (ADAP). Company Calendar Today4/19/2025Next Earnings (Estimated)5/08/2025Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:INBP CIK1016504 Webwww.integratedbiopharma.com Phone(973) 926-0816Fax973-926-1735Employees150Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.03 Trailing P/E Ratio9.67 Forward P/E RatioN/A P/E GrowthN/ANet Income$110,000.00 Net Margins1.78% Pretax Margin2.79% Return on Equity4.79% Return on Assets3.54% Debt Debt-to-Equity RatioN/A Current Ratio3.26 Quick Ratio1.27 Sales & Book Value Annual Sales$50.32 million Price / Sales0.17 Cash Flow$0.04 per share Price / Cash Flow7.35 Book Value$0.65 per share Price / Book0.45Miscellaneous Outstanding Shares30,301,000Free Float9,939,000Market Cap$8.79 million OptionableNot Optionable Beta0.86 Social Links 10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (OTCMKTS:INBP) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Integrated BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Integrated BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.